Investigators demonstrated that their robust, patient-derived xenograft (PDX) model for myelodysplastic syndrome was applicable as a preclinical platform to address pending clinical questions by interrogating the efficacy and safety of the thrombopoietin receptor agonist eltrombopag.
[Leukemia]
7992332
{7992332:88ABE4IK}
apa
50
1
163932
https://www.stemcellsciencenews.com/wp-content/plugins/zotpress/
